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ABSTRACT
Chronic, nonhealing wounds consume a great deal of healthcare resources and are a
major public health problem, associated with high morbidity and significant economic
costs. Skin grafts are commonly used to facilitate wound closure. The grafts can come
from the patient’s own skin (autograft), a human donor (allograft), or from a different
species (xenograft). A fish skin xenograft from cold-water fish (Atlantic cod, Gadus
morhua) is a relatively recent option that shows promising preclinical and clinical results
in wound healing. Chronic wounds vary greatly in etiology and nature, requiring large
cohorts for effective comparison between therapeutic alternatives. In this study, we
attempted to imitate the status of a freshly debrided chronic wound by creating acute
full-thickness wounds, 4 mm in diameter, on healthy volunteers to compare two mate-
rials frequently used to treat chronic wounds: fish skin and dHACM. The purpose is to
give an indication of the efficacy of the two therapeutic alternatives in the treatment of
chronic wounds in a simple, standardized, randomized, controlled, double-blind study.
All volunteers were given two identical punch biopsy wounds, one of which was treated
with a fish skin graft and the other with dehydrated human amnion/chorion membrane
allograft (dHACM). In the study, 170 wounds were treated (85 wounds per group). The
primary endpoint was defined as time to heal (full epithelialization) by blinded assess-
ment at days 14, 18, 21, 25, and 28. The superiority hypothesis was that the fish skin
grafts would heal the wounds faster than the dHACM. To evaluate the superiority
hypothesis, a mixed Cox proportional hazard model was used. Wounds treated with fish
skin healed significantly faster (hazard ratio 2.37; 95% confidence interval: (1.75–3.22;
p = 0.0014) compared with wounds treated with dHACM. The results show that acute
biopsy wounds treated with fish skin grafts heal faster than wounds treated with
dHACM.
INTRODUCTION
Grafts and materials containing components from processed
human and animal tissues are being used in a range of products
for the purpose of treating acute wounds and hard-to-heal
chronic wounds. Fish skin xenografts are a recent addition. The
grafts (Kerecis® Omega3 Wound, Kerecis, Isafjordur, Iceland)
from North Atlantic Cod (Gadus morhua) are acellular but oth-
erwise structurally intact skin tissue. The grafts are freeze-dried
and possess a shelf life of 3 years. Xenograft materials gener-
ally require extensive processing to reduce the risk of viral or
prion disease transfer.1,2 This processing requires the use of
harsh chemicals that dissolve the soluble components of the
tissue and denature its structure, leaving behind mostly insolu-
ble collagen.3 In the case of cod skin, however, no viral inacti-
vation is necessary.4 This allows for milder processing, which
retains the structural integrity and the molecular components of
the skin, including the proteoglycans, glycoproteins, soluble
collagen, elastin, laminin, fibroconectin, lipids, and the Omega-
3 polyunsaturated fatty acids (PUFAs).5,6 Previous work has
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shown these Omega-3 fatty acids to have bacterial barrier and
pain-modulating properties.7–9
Amniotic products have gained wide acceptance in wound
healing, most specifically in the treatment of diabetic foot ulcers
and venous leg ulcers. Of these products, the most commonly
used in the United States is dehydrated human amnion/chorion
membrane (dHACM; EpiFix® MiMedx Group Inc., Marietta,
GA, USA). dHACM has been shown to be very effective in
treating diabetic foot ulcers.10–14 Amniotic membrane-based
allografts are classified in the United States as donated organ
components and are currently being used in wound and soft-
tissue repair applications. While those membranes do not
undergo viral inactivation, they do undergo vigorous donor
screening. Characterization has found growth factors, cyto-
kines, and protease inhibitors within amnio-chorionic mem-
brane tissues, all of which are suggested to play a role in wound
repair.10 dHACM is composed of two membranes consisting of
multiple layers, including a single layer of nonviable epithelial
cells, a basement membrane, and an avascular connective tissue
matrix. The membrane undergoes several processing steps,
which include cleaning, immersing the material in a solution
containing antibiotics with or without rinsing, and drying.15
Primary objective
Chronic wounds vary greatly in etiology and nature, requiring
large cohorts for effective comparison between therapeutic
alternatives. In this study, we attempted to imitate the status of a
freshly debrided chronic wound by creating acute full-thickness
wounds, 4 mm in diameter, on healthy volunteers to compare
two materials frequently used to treat chronic wounds. The pur-
pose was to give an indication of the efficacy of the two thera-
peutic alternatives in the treatment of chronic wounds in a
simple, standardized, randomized, controlled, double-blind
study.
The primary objective of the study was a head-to-head
comparison of the time to heal for full-thickness wounds on
human volunteers using a 4 mm punch biopsy model.
The superiority hypothesis was that the fish skin grafts
would be faster in time to heal vs. dHACM. The null
hypothesis was therefore that there would have been no sig-
nificant difference between the treatments.
Secondary objectives
The secondary objectives were wound healing at day
28, pain, erythema, infection, and the cost of products used.
Primary endpoints
The primary endpoint was defined as time to heal by blinded
assessment of full epithelialization at days 14, 18, 21, 25,
and 28.
Secondary endpoints
The secondary endpoints were the proportion of wounds
healed at day 28 as assessed by full epithelialization, inci-
dences of pain, erythema, infection, and a cost comparison
derived from the total number of applications of each
product.
MATERIALS AND METHODS
Study design and participants
The study was a prospective, double-blinded, randomized,
comparative, clinical trial. The research protocol was approved
by the Icelandic Medicines Agency (8.1.13.1/2017090010), the
Icelandic Data Protection Authority, and the Icelandic National
Bioethics Committee (VSNb2018010033/03.01). All partici-
pants signed an informed consent form consistent with the
World Medical Association (WMA) Declaration of Helsinki
statement of ethical principles for medical research involving
human subjects.
Recruitment took place over a 2-month period, and partici-
pants were recruited using advertisements at the University of
Iceland and the Iceland University of the Arts in Reykjavik, Ice-
land. Healthy volunteers between the ages of 18 and 60 years
were included in the study. Information on demographics, vital
signs, and medical history was recorded. Volunteers were
excluded prior to randomization if they were using immunosup-
pressive treatment, anticoagulation therapy (i.e., warfarin), or
systemic corticosteroids and if they were suffering from
immune deficiency because of disease or iatrogenic, peripheral
vascular disease.Women who were pregnant, breast feeding, or
Figure 1. Representative subject followed up to the healing
of punch wounds. From top to bottom: D0, D7, D14, D25.
Wound on the left side of figure was treated with fish skin
graft, while the right wound was treated with dHACM.
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planning a pregnancy during the course of the clinical trial were
also excluded.
Each patient received two full-thickness, 4 mm punch biopsy
wounds created with a standard punch biopsy tool (Figure 1).
Participants acted as their own control, with one forearmwound
randomized to treatment with fish skin and a second wound on
the same forearm treated with dHACM. Two products—fish-
skin graft (Kerecis® Omega3 Wound, Kerecis, Isafjordur, Ice-
land) and dHACM (EpiFix® MiMedx Group Inc., Marietta,
GA, USA)—were used according to manufacturer’s instruc-
tions for use.
Two physicians conducted the study; a trial physician
applied the products, and an evaluating physician, blinded to
the treatment, assessed the wounds and did nothing else. The
blinded physician made the clinical assessment of wound clo-
sure that, following FDA guidelines, needed to be adjudicated
photographically. Three blinded external reviewers then exam-
ined all of the photographs of the wounds independently and
determined the visit at which closure occurred. Thus four
blinded wound-healing professionals evaluated the wounds.
Randomization and blinding
All participants in the study were assigned a unique identifica-
tion number, and all received both treatments. Randomization
dictated which wound, laterally or medially located, was treated
with which treatment (fish skin or dHACM). The two products
were randomly applied using an even/odd randomization
scheme. The randomization sequence was accessible to the trial
physician and the statisticians of the trial. The patient and the
evaluating physician were blinded to the randomization.
Surgery and trial schedule
After local anesthesia (lidocaine hydrochloride10mg/ml and
epinephrine 5 mcg/ml), two full-thickness, 4 mm punch
wounds, 3 cm apart, were made on the proximal anterolateral
aspect of the nondominant forearm. Hemostasis was achieved
with pressure and a 30% ferrous chloride solution. The products
were applied according to the randomization sequence followed
by a secondary dressing consisting of a waterproof, vapor-trans-
mitting, transparent plastic film with a centrally placed gauze
pad. Participants were provided with instructions on wound
care and two spare secondary dressings to use if necessary
before follow up. Participants were instructed not to remove the
trial products.
Over the 28-day study period, including the first study day,
participants had a total of seven visits. On day 3, participants
were contacted by phone by the trial physician to collect infor-
mation on the status of their wounds. The participants were seen
on days 7, 14, 18, 21, 25, and 28 for assessment of wound sta-
tus, allowing a visit 1 day later or earlier if necessary.
Wounds were assessed for erythema, infection, and reported
pain or bleeding, and a decision of healed vs. not healed was
made by the evaluating physician. An a priori erythema up to
1 mm on the wound edge was considered normal. Wider ery-
thema was noted as such, and wider erythema with infiltration
with or without exudate that exceeded that of other participants
was classified as an infection.
Upon wound inspections, no attempts were made to remove
material from the wounds. Wounds with material still visible in
the wound were deemed not healed. If the material had been
resorbed, or if it was not visible, new material was applied to
the wound. As the studied materials had no claims of absorp-
tion, no attempt was made to evaluate the amount of exudate. In
addition to the healed vs. nonhealed decision of the evaluating
physician, standardized digital photographs were taken and
used for healing assessment (Figure 1). If one of the two
wounds was determined to be healed, then no further evalua-
tions were performed on that participant.
Statistical analysis
The evaluations of four wound-healing professionals produced
a table of outcomes of healed vs. nonhealed wounds for each
time point. To estimate whether the differences in time to heal
between the studied materials in this accumulated data was sig-
nificant, a mixed-effects Cox proportional hazard model was
used. The model incorporates a fixed effect for the treatment, a
random individual effect to account for each individual receiv-
ing both wounds, and a random wound effect to account for the
variance introduced by the different reviewers of each wound.
All analysis was performed in R version 3.4.1.16 The confi-
dence interval for the proportion of wounds healed with each
of the treatments at each time point was estimated with the
Table 1. Demographic data



































Figure 2. Proportion of healed wounds at each time point
with fish skin graft (orange) and dHACM (blue). Wounds
treated with fish skin healed significantly faster with a hazard
ratio of 2.37 compared to dHACM allograft-treated wounds
(p = 0.0014). Projected healing for 50% of wounds was
22 days for fish skin product and 24 days for amniotic
product.
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bootstrap method using 2 million simulations. The model
parameters were estimated using the “coxme” package in R.17
For the cost analysis, a two-sided paired t-test was used. A Chi-




Eighty-five (85) healthy volunteers aged between 19 and
51 years were enrolled with no loss of follow up. Their average
age was 24.1 years, with a standard deviation of 4.6 years. Two
thirds were women. The cohort was primarily of Caucasian ori-
gin, consisting of 84 Caucasians and 1 participant of African
origin (Table 1).
Primary endpoint
From day 14 onward, wounds in the group treated with fish skin
healed to a greater extent on average than those treated with
dHACM (Figure 2). Wounds treated with fish skin healed sig-
nificantly faster with a hazard ratio of 2.37 (95% CI: 1.75–3.21)
and a p-value of 0.0014 compared to dHACM-treated wounds.
Using a likelihood ratio test, other available covariates, such as
age and gender, were omitted successively from the model as
they did not contribute to a significantly better model fit.
Figure 2 shows a greater proportion of healed wounds treated
with fish skin, where all reviewers were pooled. Similarly, the
healing trajectories of the source materials at each day and per
evaluator show consistent superiority of the fish skin grafts
(Figure 3). The results of the mixed effects Cox proportional
hazard model confirm this difference. The median day of
healing in both treatment arms was 25 days.
Other endpoints
A number of participants reported pruritus (n = 19), and six par-
ticipants developed a minor rash consistent with the application
area of the cover dressing surrounding both wounds and were
treated with another brand of cover dressing. Seven patients
reported mild pain or discomfort around the wound area, most
frequently experienced on the first 2 days. Two participants still
felt mild pain on day 3, and one reported intermittent pain up to
day 14 without infection or other identifiable causes or connec-
tions with other symptoms. Periwound erythema >1 mm was
noted in 10 wounds; four subjects had erythema in both
wounds, and two had erythema only in the wound treated with
fish skin. Thus, differences were not attributable to either treat-
ment type (Table 2). Two subjects (three wounds) experienced
irritation with discharge, one in the dHACM wound and the
other in both wounds. Two subjects exhibited hypergranulation
in one wound, one from each treatment arm. There was no case
of infection that needed treatment with antibiotics; the symp-
toms had subsided at the next dressing change. The fish skin
graft received 1.6 applications per subject on average, while the
dHACM received 1.4 applications per wound.
Of the 47 subjects where one wound healed before the
other, by the indication of one or more evaluators, 20 were
on the lateral side and 27 on the medial side. The difference
between them was not significant (p = 0.23).
DISCUSSION
Full-thickness acute wounds treated with fish skin grafts heal
significantly faster than wounds treated with dehydrated human
amnio-chorionic membrane. There was no difference in the
number of adverse reactions, such as mild erythema or irrita-
tion, between groups.18,19 A previously published clinical trial
of similar design showed that full-thickness acute wounds
treated with fish skin heal significantly faster than wounds
treated with porcine tissue.4 The two studies show that fish skin
grafts enable faster healing of acute wounds than amniotic tis-
sue and porcine tissue.
The wound-healing scores vary between evaluators but
show a consistent difference between treatments (Figure 3).
Several statistical methods exist that are frequently used to
analyze time-to-event curves. One of them is the Cox pro-
portional hazard model, which has been widely used in med-
ical research.20 This methodology allows data from
participants with only one wound healed to be used.
While the exact role of fish skin in accelerated healing of
these wounds requires further study, specific properties of the
fish skin are likely to be important to this result. Unlike the
manufacturing processes for mammalian tissues, the gentle
processing of the cod skin does not include viral deactivation,
preserving the natural structural and the molecular components
of the cod skin. The preservation of the natural three-
dimensional extracellular matrix structure and porosity may be

























Figure 3. Trajectories of the number of healed wounds to
time by evaluator and wound-healing material. Orange: Intact
fish skin. Blue: dHACM.
Table 2. Incidences of erythema, irritation, and infection at a
given time point (Day) over the course of the trial
dHACM, number of
wounds (day of trial)
Fish skin, number of
wounds (day of trial)
Erythema 2 (7), 2 (14) 4 (7), 2 (14)
Irritation and
discharge
1 (7), 1 (14) 1 (7)
Infection 0 0
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presence of fetal-derived growth factors.10 While there are
reports of dHCAM healing chronic diabetic foot ulcers in
1 week, this rapid healing effect was not noted in our acute
wound study.14 The total fatty acid content of cod skin consists
of >30% Omega-3 PUFAs, while human skin, amnion mem-
brane, and collagen matrix contains 0 or < 1%Omega-3 of total
fatty acid content.21 Both of these products have similar appli-
cation profiles in that they often require five or more applica-
tions to close a chronic wound.8 Therefore, if one has a
significantly higher or lower cost than the other, this difference
will increase rapidly with a multiple application strategy.
In this model, the differences in the cost of the product also
made the cost of treating wounds with dHACM significantly
higher than treating with fish skin (p = 2.51*10−16). dHACM-
treated wounds were, on average, 76% more expensive com-
pared to fish skin-treated wounds in this study. The cost was
calculated using the average sales price of dHACM ($160
USD/square cm based on 2018 Healthcare Common Procedure
Coding System code Q4131) and the average listed sales price
of fish skin ($80 USD/square cm).
This study was designed to minimize the effect of individual
variance between wounds by studying uniform, acute wounds
in healthy patients.When chronic wounds are treated with prod-
ucts such as the fish skin graft and dHACM, they need to be
thoroughly debrided. With debridement, the chronic wounds
approach the physiological state of an acute wound.22 There-
fore, results derived from studying acute wounds can have logi-
cal implications for debrided chronic wounds.
LIMITATIONS
When compared head to head to commonly used products, fish
skin has been shown to improve time to closure. However, the
routine need for reapplication for these products in clinical set-
tings and the nature of the chronic wound patient cannot be
reflected in this study design. Overall, the product has shown
superiority in this particular model; however, clinical trials on
chronic wounds are required to further validate these results.
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